Analystreport

Adaptimmune Therapeutics PLC - (NASDAQ: ADAP) was given a new $16.00 price target on by analysts at Raymond James. They now have a "buy" rating on the stock.

Adaptimmune Therapeutics plc - American Depositary Shares  (ADAP) 
Last adaptimmune therapeutics plc - american depositary shares earnings: 5/9 07:30 am Check Earnings Report